Summary
Radioligand therapy is becoming a crucial component of cancer treatment.
Approved radioligand therapy includes LUTATHERA (for GEP-NETs), XOFIGO, PLUVICTO (both for prostate cancer), and ZEVALIN (for follicular B-cell non-Hodgkin's lymphoma).
Leading companies such as Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others are currently active in the RLT domain.
Radioligand therapies (RLTs) are rapidly moving from niche options to a fou...
